About Telo Genomics

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer.

  • Management
  • Directors
  • Clinical and Scientific Advisory Board

Sherif Louis, PhD
CEO

Dr. Louis is an accomplished scientist and experienced leader in the biotechnology industry, with a focus on life sciences technology commercialization. He has held various leadership and executive positions with Canadian non-profit organizations focused on advising and coaching for-profit biotech enterprises engaged in technology development and commercialization. Dr. Louis was an early key contributor to the development of Telo Genomics 3D Telomere Technology dating back almost 15 years. Dr. Louis has also served on the Board of Directors of the Biotechnology Association of Manitoba. Dr. Louis holds a PhD degree in cancer biology from University of Manitoba, a MSc degree in industrial biochemistry from the University of Manitoba and a PMP certificate in project management.

 

Ryan Cheung
CFO & Director
Mr. Cheung, CPA, CA, has been providing accounting, management, securities regulatory compliance services to private and public-listed companies for the past fifteen years. He began his career in CA-public practice in 2003 articling with a boutique and mid-sized firm eventually specializing in Canadian listed entity compliance and related securities services. In 2008, Mr. Cheung founded Midland Chartered Accountants Ltd. Focused on providing tax and integrated accounting and advisory solutions to private companies and high net worth individuals with a heavy emphasis on maintaining strong professional relationships. Mr. Cheung’s financial expertise includes financial and accounting management, administrative services, advice relating to capital markets, managing company finances, including financial planning, management of financial risks, recordkeeping, and financial reporting, as well as strategic and tactical matters relating to budget management, pro-forma financial statement compilation, cost–benefit analysis, and forecasting needs. Mr. Cheung currently sits as a director and/or senior officer of several Canadian listed entities.

Hugh Rogers
Chairman

Mr. Rogers is an entrepreneur and lawyer with private and public start-up experience in a range of industries and operational roles. Recent work has focused on public listings and corporate restructuring in the life science and energy industries. From May 2017 to July 2017, Mr. Rogers was CEO and director of Dagobah Ventures Ltd., which subsequently acquired Clear Blue Technologies International Inc., an off-grid alternative energy company, through a share exchange, TSX-V listing transaction and concurrent financing. He continues to sit on the board as an independent director. From February 2017 to December 2018, Mr. Rogers was a director of RepliCel Life Sciences Inc., a TSX-V listed autologous cell therapy company, as it underwent a successful corporate restructuring and the completion of a strategic investment and international technology licencing agreement. From March 2015 to October 2017 he was CEO and director of Coronado Resources Ltd., a TSX-V listed natural gas co-generation company, which underwent a corporate reorganization and the disposition of distressed assets. Mr. Rogers has held several other independent board and management positions with exchange listed issuers, including currently serving on the Board of Seashore Resources Partners Corp. He holds a Bachelor of Science degree and LLB degree. He is a member in good standing of the Law Society of British Columbia.

Dr. Sabine Mai:
Founder, Director and Chair of the Clinical and Scientific Advisory Board

Dr. Mai is Canada Research Chair (Tier 1) in Genomic Instability and Nuclear Architecture of Cancer, Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science, University of Manitoba. Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at the University of Manitoba. She is also Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at the University of Manitoba. She is an internationally known researcher who has more than one hundred publications related to research on Genomics and Genomic Instability. Most recently she has contributed to a library of patents related to her work on 3D Genomic Analysis. She is the recipient of several academic awards including the Braidwood Jackson Memorial Award; the Dr. Saul Highman Memorial Award; the Rh Award (Basic Science); and the J&J Cognition Challenge (2013). She was recognized in 2015 as one of the Top 100: Canada’s Most Powerful Women and recently she was named as Tier I Canada Research Chair in Genomic Instability and Nuclear Architecture in Cancer by the Canadian Institute of Health Research. Dr. Mai has dedicated her life to the research of Cancer and other debilitating diseases. She has been instrumental in the development of innovative 3D analysis of genomic instability, which will help in diagnosing more specifically and earlier several forms of Cancer. This will allow physicians to personalize treatment and improve the quality of outcomes. During the course of more than twenty years of research she has contributed to a portfolio of patents protecting her discoveries. Her vision is to use her discoveries for the benefit of patients everywhere.


Guido Baechler
Director

Mr. Baechler is Founder of Berkeley Life Science Advisors, a diagnostic and pharma start-up consulting business that designs and leads strategic Mergers & Acquisitions, financing and Research & Development. Previously, Mr. Baechler held the position of Chief Executive Officer and President of Singulex, Inc. from 2013 – 2019 and Senior Vice President of Operations (COO) at Singulex from 2008 – 20013. Mr. Baechler came to Singulex from Roche Molecular Diagnostics, where he served as Head of Operational Project Management and Vice President of Global Program Management, serving as a member of its executive team. He also held various leadership positions at Roche within Research, Development, and Marketing in Switzerland and California during his almost twenty years with the company. Mr. Baechler holds a Bachelor’s Degree in Electrical Engineering and completed a series of executive finance and management classes at the London School of Business and at the Hass Business School in Berkeley.

 

 

 

Richard Savage
Director

Mr. Savage began his career as an Investment Advisor at Yorkton Securities (which became Richardson GMP) in 1988 and remained there 28 years. Richard was consistently one of the top producing advisors for many years. He was part of Yorkton, one of the top mining and technology firms in Canada, and a member of Yorkton’s Board of Directors 2000-2001. Throughout his career he served and managed a diverse client base of over 2,000 accounts and was responsible for raising funds for Initial Public Offerings, Private Placements, Capital Pool Companies. Richard believes in giving back to the community and served on Macquarie Group Foundation’s Board of Directors from 2009 to 2012. He is a current Director (16 years) of Artists For Kids, which provides art education for the children of British Columbia. In addition, he is a current Director (5 years) of The Gordon and Marion Smith Foundation, which supports and encourages community engagement in the arts. Mr. Savage also serves on several publicly traded companies, including Triangle Industries Ltd. And Crystal Lake Mining Corp., both TSX.V issuers.

Ryan Cheung
CFO & Director

Mr. Cheung, CPA, CA, has been providing accounting, management, securities regulatory compliance services to private and public-listed companies for the past fifteen years. He began his career in CA-public practice in 2003 articling with a boutique and mid-sized firm eventually specializing in Canadian listed entity compliance and related securities services. In 2008, Mr. Cheung founded Midland Chartered Accountants Ltd. Focused on providing tax and integrated accounting and advisory solutions to private companies and high net worth individuals with a heavy emphasis on maintaining strong professional relationships. Mr. Cheung’s financial expertise includes financial and accounting management, administrative services, advice relating to capital markets, managing company finances, including financial planning, management of financial risks, recordkeeping, and financial reporting, as well as strategic and tactical matters relating to budget management, pro-forma financial statement compilation, cost–benefit analysis, and forecasting needs. Mr. Cheung currently sits as a director and/or senior officer of several Canadian listed entities.

Dr. Sabine Mai, PhD
Director and Chair, Clinical and Scientific Advisory Board

Dr. Sabine Mai is currently Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science, University of Manitoba. She is also Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at University of Manitoba.

She is an internationally known researcher who has more than one hundred publications related to research on Genomics and Genomic Instability. Most recently she has contributed to a library of patents related to her work on 3D Genomic Analysis. She is the recipient of several academic awards including the Braidwood Jackson Memorial Award; the Dr. Saul Highman Memorial Award; the Rh Award (Basic Science); the J&J Cognition Challenge (2013). She was recognized in 2015 as one of the Top 100: Canada’s Most Powerful Women.

Dr. Mai has dedicated her life to the research of Cancer and other debilitating diseases. She has been instrumental in the development of innovative 3D analysis of genomic instability, which will help in diagnosing more specifically and earlier several forms of Cancer. This will allow physicians to personalize treatment and improve the quality of outcomes. During the course of more than twenty years of research she has contributed to a portfolio of patents protecting her discoveries. Her vision is to use her discoveries for the benefit of patients everywhere.

Kenneth C. Anderson, MD
Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics Institute Physician Kraft Family Professor of Medicine, Harvard Medical School

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School, as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

Hans Knecht, MD
Professor of Medicine and Chief, Division of Haematology at McGill University and Jewish General Hospital, Montreal

Dr. Knecht established himself as a prominent haematologist through his ground-breaking translational research on lymphoma biology. His current focus is on the molecular events leading to the transition from the mononuclear Hodgkin to the multinuclear Reed-Sternberg cell and the impact of 3D nuclear telomere organization on this transformation. Dr. Knecht received his medical degree from the University of Zurich, Switzerland with post-graduate work under both Maxime Seligmann (Haematology) and Karl Lennert (Haematopathology) in Paris and Kiel, respectively. Dr. Knecht is currently a Professor of Medicine and Chief, Division of Haematology at McGill University and Jewish General Hospital, Montreal.

Laurence Klotz, MD
Professor, Department of Surgery, University of Toronto, past Chief of Urology, Sunnybrook Health Sciences Centre, Toronto, and Chairman, World Uro-Oncology Federation

Dr. Klotz is internationally recognized for his contributions to the treatment of prostate cancer, notably for pioneering the adoption of Active Surveillance as a standard aspect of patient care. Dr. Klotz obtained his medical degree and residency training from the University of Toronto with a special fellowship in uro-oncology and tumour biology at Memorial Sloan Kettering Cancer Centre, New York. He is a widely published uro-oncologist who serves on the board or heads many medical/scientific organizations. He is a Professor, Department of Surgery, University of Toronto, past Chief of Urology, Sunnybrook Health Sciences Centre, Toronto, and Chairman, World Uro-Oncology Federation. Dr. Klotz was awarded the Order of Canada in 2014 for his contribution to prostate cancer treatment.

Darrel Drachenberg, MD
Urologic Oncologist Assistant Professor Director of Research, Manitoba Prostate Center Section of Urology, Department of Surgery, University of Manitoba Chair, Genito-Urinary Oncology Disease Site Group,Cancer Care Manitoba

Dr. Drachenberg is a urologic oncologist and researcher and strong proponent of Active Surveillance for prostate cancer patients. Dr. Drachenberg attended medical school at the University of British Columbia and urology residency at Dalhousie University. He is an American Foundation of Urology Scholar with fellowship training in urologic oncology at the National Cancer Institute in Bethesda, Maryland. He founded the  laparoscopic urology program and prostate brachytherapy, cryotherapy, and HIFU programs at the University of Manitoba where he works as assistant professor of surgery and director of research for the Manitoba Prostate Center and Section of Urology and Chair of the Genito-Urinary disease site group, CancerCare Manitoba.

Contact Us

info@telodx.com

Ph : 416-673-8487

Address

MaRS Centre, South Tower
101 College Street, Suite 200
Toronto, Ontario
Canada M5G 1L7

Contact Us

info@telodx.com
Ph : 416-673-8487

Address

MaRS Centre, South Tower
101 College Street, Suite 200
Toronto, Ontario
Canada M5G 1L7

(c) 2020 Telo Genomics . All rights reserved.

Website Designed & Maintained By :: WebStudio.ca